<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390376</url>
  </required_header>
  <id_info>
    <org_study_id>DOH99-TD-I-111-TM001</org_study_id>
    <nct_id>NCT01390376</nct_id>
  </id_info>
  <brief_title>DAAOI-1 Treatment for Treatment-resistant Schizophrenia</brief_title>
  <official_title>DAAOI-1 Treatment for Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health, Executive Yuan, R.O.C. (Taiwan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacotherapy for schizophrenia has limitations such as residual positive and negative
      symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia
      (particularly clozapine-resistant) is still a difficult clinical issue at present. According
      to the N-methyl-D-aspartate (NMDA) hypothesis, adjuvant NMDA-enhancing agents may have
      therapeutic benefit. DAAOI-1, a D-amino acid oxidase (DAAO) inhibitor, is a NMDA-enhancing
      agents.

      The aim of this project is to examine the effectiveness and safety of DAAOI-1 adjuvant
      treatment for clozapine-resistant refractory schizophrenia patients in a randomized,
      double-blind, placebo - controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacotherapy for schizophrenia has limitations such as residual positive and negative
      symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia
      (particularly clozapine-resistant) is still a difficult clinical issue at present. Among
      schizophrenia patients, around 20-25%are treatment-resistant. According to the
      N-methyl-D-aspartate (NMDA) hypothesis, many clinical trials on NMDA-enhancing agents were
      studied. Adjuvant NMDA-enhancing agents, including glycine, D-amino acids (D-serine,
      D-alanine), and sarcosine (a glycine transporter I inhibitor), revealed beneficial but
      limited efficacy for positive and negative symptoms. The investigators recently started to
      study the potential of DAAOI-1, a D-amino acid oxidase (DAAO) inhibitor which can elevate
      synaptic concentration of D-amino acids.

      The aims of this project is to examine the effectiveness and safety of DAAOI-1 adjuvant
      treatment for clozapine-resistant refractory schizophrenia patients in a randomized,
      double-blind, placebo - controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The severity of psychiatric symptoms</measure>
    <time_frame>week 0, 2, 4, 6</time_frame>
    <description>The severity of psychiatric symptoms will be assessed by:
Positive and Negative Syndrome Scale(PANSS)
Assessment of Negative symptoms(SANS)
Global assessment of function(GAF)
Quality of life scale(QOL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS subscales</measure>
    <time_frame>week 0,2,4,6</time_frame>
    <description>score changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD)</measure>
    <time_frame>Week 0,2,4, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>week 0, 6</time_frame>
    <description>7 domains of Measurement and Treatment Research to Improve Cognition in Schizophrenia&quot; [MATRICS]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BE 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAAOI-1 1g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BE 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAAOI-1 2g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>starch pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAAOI-1</intervention_name>
    <description>DAAOI-1 1g</description>
    <arm_group_label>BE 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAAOI-1</intervention_name>
    <description>DAAOI-1 2g</description>
    <arm_group_label>BE 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>starch pill</description>
    <arm_group_label>starch pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilled the DSM-IV criteria of schizophrenia

          -  Poor responder of clozapine: a 12-week treatment without satisfactory response: a
             minimal total score of 70 on the Positive and Negative Syndrome Scale (PANSS) (Kay
             1987), and a minimal total score of 40 on the Scale for the Assessment of Negative
             Symptoms (SANS) (Andreasen 1983).

          -  Agree to participate in the study and provide informed consent

        Exclusion Criteria:

          -  Meet DSM-IV criteria of other AXIS I disorder, current substance dependence or mental
             retardation

          -  Serious medical or neurological illness

          -  Pregnancy or lactation

          -  Use of depot antipsychotic in the past 6 months

          -  Inability to follow protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Hsien-Yuan Lane</investigator_full_name>
    <investigator_title>Departement of psychiatry, China Medical University Hospital</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>NMDA</keyword>
  <keyword>DAAOI</keyword>
  <keyword>Clozapine resistant schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

